Transplant recipients are at risk for poor outcomes from coronavirus disease 2019 (COVID-19) due to frequent medical comorbidities and presence of immunosuppression. Observational cohort studies suggest that patients after lung transplantation (LTx) with COVID-19 may have higher mortality in comparison to other solid organ transplant recipients. In a US retrospective analysis in the beginning of 2020, 78% of infected transplant patients were hospitalised and 19% died within 28 days [1]. Recently, both mortality and hospitalisation rate have declined in transplanted patients [2] and reduced mortality has been associated with vaccination [3].

由于频繁的医学合并症和免疫抑制的存在，移植受者面临 2019 年冠状病毒病 (COVID-19) 的不良预后风险。观察性队列研究表明，与其他实体器官移植受者相比，肺移植 (LTx) 后 COVID-19 患者的死亡率可能更高。在 2020 年初的一项美国回顾性分析中，78% 的感染移植患者住院治疗，19% 的患者在 28 天内死亡 [1]。最近，移植患者的死亡率和住院率均有所下降 [2]，而死亡率的降低与疫苗接种有关 [3]。